07/11/2025
Vitiligo is a chronic autoimmune skin disorder affecting up to 2% of the global population. Current treatments (topical corticosteroids, phototherapy, immunomodulators) are limited, slow to act, andoften inaccessible in low-resource settings. There is an unmet global need for safe, effective, andaffordable therapies that restore pigmentation and improve quality of life.We have developed a novel botanical-based oral formulation that has shown clinically significantre-pigmentation in vitiligo patients under real-world conditions. Over a 4-month observationalprogram, multiple patients demonstrated visible and measurable re-pigmentation, as documented inbefore/after photographs. Safety has been favorable, with only mild, transient side effects(occasional itching or body heat sensation).This positions our therapy at Proof of Concept (PoC) stage: we have demonstrated human efficacybeyond anecdotal reports, with reproducible results across different patients, but now requirestructured clinical validation.
